News & Updates
Filter by Specialty:
Smoking, prolonged catheterization a major risk factor for UTI after radical hysterectomy
For women with cervical cancer who are undergoing radical hysterectomy, preoperative tobacco use and prolonged catheterization appear to contribute to an increased risk of developing postoperative catheter-associated urinary tract infections (UTIs), as reported in a study.
Smoking, prolonged catheterization a major risk factor for UTI after radical hysterectomy
13 Mar 2023
Weight status influences urinary function recovery after radical prostatectomy
Among prostate cancer patients, those without obesity are more likely to experience earlier recovery in urinary function after radical prostatectomy and have better sexual function both before and after the procedure, as reported in a study.
Weight status influences urinary function recovery after radical prostatectomy
10 Mar 2023
Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?
In patients with metastatic castration-sensitive prostate cancer, triplet therapy may be ideal for fit patients with synchronous (de novo) high-volume disease while the androgen pathway inhibitor (API) doublet combinations may be preferred for those with metachronous (recurrent) low-volume disease, according to the results of a meta-analysis.
Metastatic castration-sensitive prostate cancer: When is it preferable to use triplet, doublet therapies?
10 Mar 2023
mHSPC: Adding darolutamide to ADT and docetaxel ups OS in most disease volume and risk subgroups
Triplet therapy with darolutamide, androgen-deprivation therapy (ADT) and docetaxel improves overall survival (OS) by approximately 30 percent vs ADT plus docetaxel in most disease volume and risk subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC), a post hoc analysis of the phase III ARASENS trial has shown.
mHSPC: Adding darolutamide to ADT and docetaxel ups OS in most disease volume and risk subgroups
10 Mar 2023
Mobile app captures symptoms, biometrics of bladder cancer patients after cystectomy
Patients with bladder cancer who underwent radical cystectomy may benefit from the use of smartphones and wearable technology to monitor their symptoms as well as biometric data, according to a recent study.
Mobile app captures symptoms, biometrics of bladder cancer patients after cystectomy
08 Mar 2023
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer
In the extended follow up of the phase III CheckMate 274 trial, nivolumab continued to show benefit for patients with muscle-invasive urothelial carcinoma (MIUC; bladder, ureter, or renal pelvis) who were at high risk for recurrence following bladder resection.
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer
08 Mar 2023
Darolutamide-containing triplet regimen ups survival in mHSPC regardless of disease volume, risk
In a post hoc analysis of the phase III ARASENS study, the triplet regimen comprising darolutamide, androgen deprivation therapy (ADT), and docetaxel continued to show overall survival (OS) benefit for metastatic hormone-sensitive prostate cancer (mHSPC) irrespective of disease volume and risk.
Darolutamide-containing triplet regimen ups survival in mHSPC regardless of disease volume, risk
06 Mar 2023
Rucaparib improves rPFS vs docetaxel or 2nd-generation ARPI in BRCA-mutated mCRPC
Rucaparib significantly improves radiographic progression-free survival (rPFS) vs physician’s choice of docetaxel, abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) harbouring BRCA alterations whose disease has progressed after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI), results of the phase III TRITON3 trial have shown.